KIF18A-IN-2

Research use only, not for human use.

KIF18A-IN-2 is an inhibitor of mitotic kinesin Kif18A with IC50 of 28 nM and can be used in studies about chromosomal instability-associated vulnerabilities.

KIF18A-IN-2 is an inhibitor of mitotic kinesin Kif18A with IC50 of 28 nM and can be used in studies about chromosomal instability-associated vulnerabilities.(In Vivo):In Female athymic nude mice injected with human OVCAR-3 HGSOC cells, KIF18A-IN-2 (100 mg/kg; i.p.) exhibits a significant and sustained pharmacodynamic response and increases the number of mitotic cells (pH3 positive cells) in tumor tissues.

——

KIF18A-IN-2 (compound 23) (100 mg/kg; i.p., single) exhibits a significant and sustained pharmacodynamic response, increasing the number of mitotic cells (pH3 positive cells) in tumor tissues for up to 24 hours.Pharmacokinetic Parameters of KIF18A-IN-2 in female CD-1 mice.Animal Model:Female athymic nude mice (4-7 weeks; injected with human OVCAR-3 HGSOC cells)Dosage:100 mg/kg Administration:i.p., single Result:Showed a significant and sustained pharmacodynamic response, increasing the number of mitotic cells (pH3 positive cells) in tumor tissues for up to 24 hours.

——

Cytoskeleton/Cell Adhesion Molecules

Microtubule/Tubulin

——

——

——

2600559-20-2

534.69

C25H34N4O5S2

>98% (HPLC)

In Vitro:?DMSO : 50 mg/mL (93.51 mM)

O=C(NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C)C2=CC=C(C=C2N3CCC4(CC3)CC4)NS(=O)(=O)C

——

(-20℃)

With Ice Pack

≥ 2 years